An observational study in Follicular Lymphoma, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-24.
Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Observational
The purpose of this study is to characterise the long-term safety of lisocabtagene maraleucel, focusing on patients treated in the approved follicular lymphoma (FL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities
5,578 studies on the registry are indexed under Lymphoma; 825 are open to participants now.
This study's planned enrollment of 300 is above the median of 136 across 625 observational studies indexed under Lymphoma.
Browse Lymphoma studies →Juno Therapeutics, Inc., a Bristol-Myers Squibb Company is the lead sponsor of 17 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will include adults with relapsed/refractory follicular lymphoma that are being treated with lisocabtagene maraleucel and are registered within the Center for International Blood and Marrow Transplant Research (CIBMTR) registry.
Exclusion Criteria:
Biological: Lisocabtagene maraleucel
As per product label
Incidence of adverse events (AEs) of interest
AEs of interest include: * Secondary malignancies * Cytokine release syndrome (CRS) Grade ≥ 3 * Neurotoxicity Grade ≥ 3 * Prolonged cytopenias * Pregnancy outcome * Tumor lysis syndrome (TLS) Grade ≥ 3 * Serious infections (ie, those requiring treatment) * Organ toxicities Grade ≥ 3 * Hemophagocytic lymphohistiocytosis (HLH)/ macrophage activation syndrome (MAS)-like toxicities * Aggravated graft-versus-host disease (GvHD)
Time frame: Up to 15 years
Incidence of other adverse events (AEs) of interest
Other clinically important events that have not yet been identified as part of the liso-cel safety profile
Time frame: Up to 15 years
Overall survival (OS)
Time frame: Up to 15 years
Overall response rate (ORR)
Time frame: Up to 15 years
Complete remission rate (CRR)
Time frame: Up to 15 years
Duration of response (DOR)
Time frame: Up to 15 years
Progression-free survival (PFS)
Time frame: Up to 15 years
Time to next treatment (TTNT)
Time frame: Up to 15 years
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company